Polyrizon (NASDAQ:PLRZ) & QIAGEN (NYSE:QGEN) Head to Head Survey

QIAGEN (NYSE:QGEN) and Polyrizon (NASDAQ:PLRZ) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Earnings & Valuation

This table compares QIAGEN and Polyrizon”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QIAGEN	$1.98 billion	5.18	$83.59 million	$1.69	27.26
Polyrizon	N/A	N/A	-$1.54 million	N/A	N/A

QIAGEN has higher revenue and earnings than Polyrizon.

Profitability

This table compares QIAGEN and Polyrizon’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
QIAGEN	18.30%	14.77%	8.87%
Polyrizon	N/A	N/A	N/A

Institutional & Insider Ownership

70.0% of QIAGEN shares are held by institutional investors. 9.0% of QIAGEN shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for QIAGEN and Polyrizon, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QIAGEN	0	8	3	0	2.27
Polyrizon	0	0	0	0	0.00

QIAGEN presently has a consensus target price of $49.69, suggesting a potential upside of 7.87%. Given QIAGEN’s stronger consensus rating and higher possible upside, equities analysts clearly believe QIAGEN is more favorable than Polyrizon.

Summary

QIAGEN beats Polyrizon on 10 of the 10 factors compared between the two stocks.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

About Polyrizon

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.